Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Other Non-Current Liabilities (2016 - 2026)

Standard Biotools has reported Other Non-Current Liabilities over the past 16 years, most recently at $1.2 million for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 14.41% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, up 14.41% year-over-year, with the annual reading at $1.2 million for FY2025, 14.41% up from the prior year.
  • Other Non-Current Liabilities was $1.2 million for Q4 2025 at Standard Biotools, up from $1.2 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $3.5 million in Q1 2025 and troughed at $276000.0 in Q2 2021.
  • The 5-year median for Other Non-Current Liabilities is $1.2 million (2022), against an average of $1.3 million.
  • Year-over-year, Other Non-Current Liabilities plummeted 63.19% in 2023 and then surged 412.73% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $882000.0 in 2021, then increased by 8.96% to $961000.0 in 2022, then rose by 10.82% to $1.1 million in 2023, then decreased by 0.28% to $1.1 million in 2024, then rose by 14.41% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Other Non-Current Liabilities are $1.2 million (Q4 2025), $1.2 million (Q3 2025), and $1.2 million (Q2 2025).